Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2024
Reporting Period: Specific event date (May 14, 2024)
This filing reports the entry into a material definitive agreement involving the issuance of Series B Preferred Stock to the Chief Executive Officer and details regarding an upcoming shareholder vote to increase authorized common stock.
Key Financial Metrics
Transaction Value: $100.00 (Purchase price for one share of Series B Preferred Stock).
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a current report on specific corporate actions, not a periodic financial statement.
Material Changes and Corporate Actions
- Series B Preferred Stock Issuance: On May 14, 2024, the Company sold one share of newly designated Series B Preferred Stock to CEO Timothy Warbington for $100.00.
- Voting Rights Structure: The Series B Preferred Stock carries no general voting rights but grants 100,000,000 votes specifically on the "Share Increase Proposal." These votes must be cast in the same proportion as the common stock votes on that specific proposal.
- Redemption Terms: The Series B Preferred Stock will be automatically redeemed upon approval of the Share Increase Proposal or at the Board's discretion.
- Share Increase Proposal: The Company proposes to amend its Articles of Incorporation to increase authorized common stock from 5,000,000 to 25,000,000 shares.
- Annual Meeting: Scheduled for July 19, 2024, with a record date of June 3, 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the mechanics of the preferred stock issuance to facilitate the shareholder vote on the share increase. The sale was exempt from registration under Section 4(a)(2) of the Securities Act of 1933 as the purchaser is an accredited investor.
Risks and Contingencies: The filing does not explicitly list new risk factors, though the automatic redemption of the preferred stock is contingent upon shareholder approval of the share increase.
Investor Verification Checklist
- Verify the terms of the Certificate of Designation for Series B Preferred Stock (Exhibit 3.1) to confirm voting mechanics and redemption triggers.
- Confirm the outcome of the Share Increase Proposal at the Annual Meeting on July 19, 2024.
- Review the preliminary proxy statement filed on May 16, 2024, for additional context on the proposed capital structure changes.
- Monitor the redemption status of the Series B Preferred Stock following the shareholder vote.